272.81MMarket Cap-11.39P/E (TTM)
6.510High6.190Low65.36KVolume6.330Open6.250Pre Close417.98KTurnover0.27%Turnover RatioLossP/E (Static)42.76MShares6.81852wk High5.69P/B153.63MFloat Cap2.14052wk Low--Dividend TTM24.08MShs Float10.880Historical High--Div YieldTTM5.12%Amplitude1.120Historical Low6.394Avg Price1Lot Size
DiaMedica Therapeutics Stock Forum
Revolutionary Stroke Treatment Mechanism Revealed: How DM199 Could Transform Patient Care
4 MINUTES AGO, 8:15 AM EST
VIA BUSINESSWIRE
Scientific insight into DM199's mechanism for increasing collateral circulation and salvaging brain tissue at-risk from infarction
DiaMedica Therapeutics Announces Publication of DM199's Mechanism of Action for the Treatment of Acute Ischemic Stroke (AIS) in the Journal Stroke
Thursday, 20th February at 8:15 am
Scientific insight into DM199's mechanism for increasing collateral circulation and salvaging brain tissue at-risk from infarction
DiaMedica Therapeutics Inc. (NASDAQ: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic dis...
2 MINUTES AGO, 8:27 AM EDT
VIA BUSINESSWIRE
• Dosing first participant expected in the fourth quarter of 2024 with preliminary proof-of-concept results targeted for the first half of 2025
DiaMedica Therapeutics Announces Regulatory Approval to Begin Phase 2 Trial of DM199 in the Treatment of Preeclampsia
• Dosing first participant expected in the fourth quarter of 2024 with preliminary proof-of-concept results targeted for the first half of 2025
DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, today announced regulatory approval has been...
DiaMedica Therapeutics Announces $11.8 Million Private Placement
NEWS
DiaMedica Therapeutics Announces First Patient Dosed in Relaunch of its Pivotal Phase 2/3 ReMEDy2 Trial of DM199 for the Treatment of Acute Ischemic Stroke
No comment yet